JOHNSON DAVID LEE 4

What Happened David L. Johnson, Chief Operating Officer of Vera Therapeutics (VERA), received equity awards on February 4, 2026 totaling 60,000 share-equivalents. The filing shows 20,000 shares acquired (A) at $0.00 and an additional 40,000 listed as a derivative award at $0.00 — total reported value $0 on grant. These awards are equity compensation grants (not open-market purchases or sales).

Key Details

• Transaction date: February 4, 2026; Form 4 filed February 6, 2026 (timely filing).
• Grants reported: 20,000 shares @ $0.00 (direct) and 40,000 derivative shares @ $0.00; combined = 60,000 RSU-type awards.
• Vesting (per footnote F1): One-fourth of the RSUs vests on each of Feb 20, 2027, 2028, 2029 and 2030, subject to continuous service.
• Prior holdings (per footnote F2): includes 643 shares acquired Mar 13, 2025 and 763 shares acquired Sept 12, 2025 under the company ESPP.
• Additional equity detail (per footnote F3): a separate stock option grant vests 1/48th beginning Mar 4, 2026 and monthly thereafter (this is a different award, not the Feb 4 RSU grant).
• Shares owned after transaction: not specified in the supplied details of this summary.

Context

• These are grant awards (A) — typical executive compensation intended to retain employees; they do not represent a purchase (bullish) or sale (liquidation) signal by themselves.
• The 40,000 amount is reported as a derivative (RSU-style) award; no cash changed hands at grant and shares are subject to future vesting conditions.
• For retail investors, grants can dilute existing shares over time as they vest but do not indicate immediate insider buying or selling activity.